Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced the publication of peer-reviewed Phase 1 data for TNX-1500, its investigational anti-CD40L monoclonal antibody, in the Journal of Clinical Immunology. The study highlights favorable safety, tolerability and pharmacodynamic results in healthy volunteers, supporting the advancement of the candidate into a planned Phase 2 investigator-initiated kidney transplant rejection study in the second half of 2026, pending FDA clearance.
The Phase 1 study found that TNX-1500 was generally well tolerated with no serious adverse events. It demonstrated sustained suppression of T cell-dependent antibody responses and showed a half-life that supports monthly intravenous dosing. These results are critical for the development of TNX-1500 as a potential treatment to prevent kidney transplant rejection, a significant unmet medical need in the field of transplantation.
The publication of this data marks an important milestone for Tonix Pharmaceuticals, a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra.
Beyond CNS, Tonix is advancing a pipeline of immunology programs. TNX-1500 represents a third-generation CD40 ligand inhibitor designed to modulate the immune response in transplant rejection. The planned Phase 2 study is an investigator-initiated trial that will evaluate TNX-1500 in kidney transplant recipients, a population that currently relies on chronic immunosuppression with significant side effects.
The implications of this announcement are far-reaching. If successful, TNX-1500 could offer a new option for preventing organ rejection, potentially improving outcomes for kidney transplant patients. The favorable Phase 1 data suggest that TNX-1500 may have a favorable safety profile compared to earlier anti-CD40L antibodies, which were associated with thromboembolic events. The sustained pharmacodynamic effect and convenient monthly dosing could also improve patient compliance.
For the biotechnology industry, this advancement underscores the potential of CD40L inhibition in transplantation and autoimmune diseases. Tonix's progress with TNX-1500 adds to its diverse pipeline, which includes TNX-4800 for Lyme disease prophylaxis and TNX-2900 for Prader-Willi syndrome.
Investors and stakeholders can follow the latest news and updates relating to TNXP in the company’s newsroom at https://ibn.fm/TNXP. The full press release detailing the Phase 1 data is available at https://ibn.fm/DHiKX.
